Showing 1-10 of about 109 articles.
TranS1 Inc.
TranS1 Inc. Schedules First Quarter 2013 Results Conference Call for Thursday, May 9, 2013
RALEIGH, N.C., April 26, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release first quarter 2013 financial and operating results, and provide an update on the company's acquisition of Baxano, Inc. ("Baxano"), after market close on Thursday, May 9, 2013. Ken Reali, President and Chief Executive Officer of TranS1, and Joe Slattery, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 881-2183 for domestic callers and (970) 315-0453 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at
TranS1 Inc.
TranS1 Inc. Schedules Fourth Quarter 2012 Results Conference Call for Monday, March 4, 2013
WILMINGTON, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release fourth quarter 2012 financial and operating results after market close on Monday, March 4, 2013. Ken Reali, President and Chief Executive Officer of TranS1, and Joe Slattery, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 881-2183 for domestic callers and (970) 315-0453 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at
TranS1 Inc.
TranS1 Appoints Mark Stautberg to Board of Directors
WILMINGTON, N.C., Feb. 19, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing spine products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has appointed Mark Stautberg to serve on its Board of Directors. Mr. Stautberg has over thirty years of experience in management and sales in the medical device industry.
TranS1 Inc.
TranS1 Inc. Announces Coverage Milestone
WILMINGTON, N.C., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region, announced today that the company estimates that the total number of commercial and Federal Government lives covered for pre-sacral interbody fusion now exceeds 50 million, a significant milestone for pre-sacral interbody fusion coverage utilizing its proprietary AxiaLIF® implant. In addition, Medicare represents another 50 million covered lives divided into 15 different jurisdictions that typically cover Category I Codes that have assigned dollar values. CPT Code 22586, utilized for pre-sacral interbody fusion, was assigned a value by Medicare in November 2012.
TranS1 Inc.
TranS1 Inc. Announces Preliminary Unaudited Fourth Quarter 2012 Revenue
WILMINGTON, N.C., Jan. 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announced its preliminary unaudited revenue for the fourth quarter ended December 31, 2012.
Showing 1-10 of about 109 articles.